Cargando…

Is papillary thyroid microcarcinoma an indolent tumor?: A retrospective study on 280 cases treated with radioiodine

The increasing detection of papillary thyroid microcarcinoma (PTMC) has created management dilemmas. To clarify the clinical significance of postsurgery stimulated thyroglobulin (ps-Tg) in PTMC who undergo thyroidectomy and radioactive iodine (RAI), we retrospectively reviewed the 358 PTMC patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Xuemei, Zhang, Xiao, Zhang, Yajing, Hua, Wenjuan, Maimaiti, Yusufu, Gao, Zairong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059077/
https://www.ncbi.nlm.nih.gov/pubmed/27749574
http://dx.doi.org/10.1097/MD.0000000000005067
_version_ 1782459373152370688
author Gao, Xuemei
Zhang, Xiao
Zhang, Yajing
Hua, Wenjuan
Maimaiti, Yusufu
Gao, Zairong
author_facet Gao, Xuemei
Zhang, Xiao
Zhang, Yajing
Hua, Wenjuan
Maimaiti, Yusufu
Gao, Zairong
author_sort Gao, Xuemei
collection PubMed
description The increasing detection of papillary thyroid microcarcinoma (PTMC) has created management dilemmas. To clarify the clinical significance of postsurgery stimulated thyroglobulin (ps-Tg) in PTMC who undergo thyroidectomy and radioactive iodine (RAI), we retrospectively reviewed the 358 PTMC patients who were treated with RAI and followed up in our hospital. Those with an excessive anti-Tg antibody, ultrasound-detected residual were excluded, thereby resulting in the inclusion of 280 cases. Their clinical and histopathological information and clinical outcomes were collected and summarized. Tumor stages were classified according to the tumor, node, metastasis (TNM) staging system and the consensus of the European Thyroid Association (ETA) risk stratification system, respectively. Kaplan–Meier curves were constructed to compare the disease-free survival (DFS) rates of different risk-staging systems. By the end of follow-up, none of the patients died of the disease or relapsed. The 8-year DFS rate was 76.9%. Kaplan–Meier curves showed different DFS rates in TNM stages I versus IV, III versus IV, very low risk versus high risk, low risk versus high risk, respectively (P < 0.05), while they were not significantly different in stage I versus stage III, very low risk versus low risk (P > 0.05). Finally, 40 (14.3%) cases got a persistent disease. Five variables (male sex, nonconcurrent benign pathology, initial tumor size >5 mm, lymph node metastasis, and ps-Tg ≥ 10 μg/L) were associated with disease persistence by univariate regression analysis. Ps-Tg ≥ 10 μg/L was the only independent prognostic variable that predicted disease persistence by multivariate regression analysis (odds ratio: 36.057, P = 0.000). Therefore, PTMC with a small size of ≤1 cm does not always act as an indolent tumor. In conclusion, ps-Tg ≥ 10 μg/L is associated with increased odds of disease persistence. ETA risk stratification is more effective in predicting disease persistence than the TNM classification system.
format Online
Article
Text
id pubmed-5059077
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-50590772016-11-01 Is papillary thyroid microcarcinoma an indolent tumor?: A retrospective study on 280 cases treated with radioiodine Gao, Xuemei Zhang, Xiao Zhang, Yajing Hua, Wenjuan Maimaiti, Yusufu Gao, Zairong Medicine (Baltimore) 5700 The increasing detection of papillary thyroid microcarcinoma (PTMC) has created management dilemmas. To clarify the clinical significance of postsurgery stimulated thyroglobulin (ps-Tg) in PTMC who undergo thyroidectomy and radioactive iodine (RAI), we retrospectively reviewed the 358 PTMC patients who were treated with RAI and followed up in our hospital. Those with an excessive anti-Tg antibody, ultrasound-detected residual were excluded, thereby resulting in the inclusion of 280 cases. Their clinical and histopathological information and clinical outcomes were collected and summarized. Tumor stages were classified according to the tumor, node, metastasis (TNM) staging system and the consensus of the European Thyroid Association (ETA) risk stratification system, respectively. Kaplan–Meier curves were constructed to compare the disease-free survival (DFS) rates of different risk-staging systems. By the end of follow-up, none of the patients died of the disease or relapsed. The 8-year DFS rate was 76.9%. Kaplan–Meier curves showed different DFS rates in TNM stages I versus IV, III versus IV, very low risk versus high risk, low risk versus high risk, respectively (P < 0.05), while they were not significantly different in stage I versus stage III, very low risk versus low risk (P > 0.05). Finally, 40 (14.3%) cases got a persistent disease. Five variables (male sex, nonconcurrent benign pathology, initial tumor size >5 mm, lymph node metastasis, and ps-Tg ≥ 10 μg/L) were associated with disease persistence by univariate regression analysis. Ps-Tg ≥ 10 μg/L was the only independent prognostic variable that predicted disease persistence by multivariate regression analysis (odds ratio: 36.057, P = 0.000). Therefore, PTMC with a small size of ≤1 cm does not always act as an indolent tumor. In conclusion, ps-Tg ≥ 10 μg/L is associated with increased odds of disease persistence. ETA risk stratification is more effective in predicting disease persistence than the TNM classification system. Wolters Kluwer Health 2016-10-07 /pmc/articles/PMC5059077/ /pubmed/27749574 http://dx.doi.org/10.1097/MD.0000000000005067 Text en Copyright © 2016 the Author(s). Published by Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0
spellingShingle 5700
Gao, Xuemei
Zhang, Xiao
Zhang, Yajing
Hua, Wenjuan
Maimaiti, Yusufu
Gao, Zairong
Is papillary thyroid microcarcinoma an indolent tumor?: A retrospective study on 280 cases treated with radioiodine
title Is papillary thyroid microcarcinoma an indolent tumor?: A retrospective study on 280 cases treated with radioiodine
title_full Is papillary thyroid microcarcinoma an indolent tumor?: A retrospective study on 280 cases treated with radioiodine
title_fullStr Is papillary thyroid microcarcinoma an indolent tumor?: A retrospective study on 280 cases treated with radioiodine
title_full_unstemmed Is papillary thyroid microcarcinoma an indolent tumor?: A retrospective study on 280 cases treated with radioiodine
title_short Is papillary thyroid microcarcinoma an indolent tumor?: A retrospective study on 280 cases treated with radioiodine
title_sort is papillary thyroid microcarcinoma an indolent tumor?: a retrospective study on 280 cases treated with radioiodine
topic 5700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059077/
https://www.ncbi.nlm.nih.gov/pubmed/27749574
http://dx.doi.org/10.1097/MD.0000000000005067
work_keys_str_mv AT gaoxuemei ispapillarythyroidmicrocarcinomaanindolenttumoraretrospectivestudyon280casestreatedwithradioiodine
AT zhangxiao ispapillarythyroidmicrocarcinomaanindolenttumoraretrospectivestudyon280casestreatedwithradioiodine
AT zhangyajing ispapillarythyroidmicrocarcinomaanindolenttumoraretrospectivestudyon280casestreatedwithradioiodine
AT huawenjuan ispapillarythyroidmicrocarcinomaanindolenttumoraretrospectivestudyon280casestreatedwithradioiodine
AT maimaitiyusufu ispapillarythyroidmicrocarcinomaanindolenttumoraretrospectivestudyon280casestreatedwithradioiodine
AT gaozairong ispapillarythyroidmicrocarcinomaanindolenttumoraretrospectivestudyon280casestreatedwithradioiodine